StockNews.AI
ABBV
StockNews.AI
144 days

Regulatory Condition Satisfied for License Agreement between AbbVie and Gubra

1. AbbVie and Gubra's obesity treatment partnership progresses after FTC approval. 2. The license agreement for GUB014295 is pending customary closing conditions.

2m saved
Insight
Article

FAQ

Why Bullish?

The collaboration with Gubra could lead to a significant revenue stream if successful, similar to AbbVie's past success with Humira.

How important is it?

The partnership enhances AbbVie's pipeline, addressing a rising obesity epidemic with potential high demand.

Why Long Term?

Successful development of GUB014295 may take years but could establish AbbVie in the obesity market.

Related Companies

GUBRA
HØRSHOLM, DK / ACCESS Newswire / March 28, 2025 / Gubra (CPH:GUBRA) With reference to AbbVie's (NYSE:ABBV) and Gubra A/S' (CPSE:GUBRA) joint announcement of March 3, 2025 regarding a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity, the US Federal Trade Commission today granted early termination of the waiting period under the HSR Act. Closing of the license agreement remains subject to other customary closing conditions.

Related News